Trinity Biotech Plc · NASDAQ:TRIB
Trinity Biotech — Q3 2025 Earnings Presentation
15 slides from Trinity Biotech's earnings presentation, Sep 30, 2025
Slide 1: Financial Results (Unaudited) For Quarter Ended September 30, 2025
Financial Results (Unaudited) For Quarter Ended September 30, 2025
Slide 2: Q3 2025 Financial Results - Summary
Q3 2025 Financial Results - Summary Overview • Revenue for the quarter ended as of 30 September 2025 on a like-for-like basis (excluding sub-scale lower- margin third-party product lines) was $14.2m vs Q3, 2024 $14.6m. • The Company experienced significant quarter-on-quarter increase in revenue in Q
Slide 3: Q3 2025 Revenue & Gross Profit
Q3 2025 Revenue & Gross Profit Revenue Overview • Total revenue: $14.3m, compared to $15.2m in Q3, 2024. • Like-for-like revenue (excluding sub-scale lower-margin third-party product lines being discontinued): Q3, 2025: $14.2m vs Q3, 2024 $14.6m. • Revenue movements in Q3’25 compared to Q3, 2024 wer
Slide 4: Q3 2025 Cost Base & Liquidity
Q3 2025 Cost Base & Liquidity • R&D expense: (Q3, 2025: $0.8m vs Q3 2024: $1.0m), with $1.7m capitalised including $1.0m for CGM programme. • SG&A expense: (Q3, 2025: $6.2m vs Q3, 2024: $6.5m) with decrease driven primarily by cost reductions associated with the Comprehensive Transformation Plan par
Slide 5: Net Financing Expense
Net Financing Expense Three Months Ended Nine Months Ended (US$’000’s) September 30, September 30, 2025 2024 2025 2024 Amended Term Loan interest 3,635 3,224 10,327 8,841 Convertible note interest 309 292 914 863 Notional interest on lease liabilities for Right-of-use assets 158 152 479 449 Fair val
Slide 6: EBITDA & Adjusted EBITDA Reconciliation
EBITDA & Adjusted EBITDA Reconciliation Three Months Ended Nine Months Ended (US$’000’s) September 30, September 30, 2025 2024 2025 2024 Loss for the period on continuing operations (5,135) (4,759) (19,900) (14,833) Income tax expense/ (credit) 73 (35) 373 (99) Net financing expense 4,285 2,236 8,71
Slide 7: Use of Non-IFRS Financial Measures
Use of Non-IFRS Financial Measures The attached summary unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentatio
Slide 8: Forward-Looking Statements
Forward-Looking Statements This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resour
Slide 9: About Trinity Biotech
About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a variety of health conditions including autoimmune, infectious and sexually transm
Slide 10: Consolidated Statement of Operations (unaudited)
Trinity Biotech PLC Consolidated Statement of Operations (unaudited) (US$000’s except share and per data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues 14,312 15,152 32,713 45,698 Cost of sales (7,844) (9,844) (19,724) (29,134) Gross profit 6,468 5,308
Slide 11: Consolidated Balance Sheets
Trinity Biotech PLC Consolidated Balance Sheets (US$000’s) September 30, June 30, March 31, December 31, 2025 2025 2025 2024 (unaudited) (unaudited) (unaudited) (audited) ASSETS Non-current assets Property, plant and equipment 4,011 4,309 4,382 4,621 Goodwill and intangible assets 57,813 55,919 53,6
Slide 12: Consolidated Balance Sheets - continued
Trinity Biotech PLC Consolidated Balance Sheets - continued (US$000’s) September 30, June 30, March 31, December 31, 2025 2025 2025 2024 (unaudited) (unaudited) (unaudited) (audited) EQUITY AND LIABILITIES - continued Current liabilities Income tax payable 487 472 390 364 Trade and other payables 30
Slide 13: Consolidated Statement of Cash Flows (unaudited)
Trinity Biotech PLC Consolidated Statement of Cash Flows (unaudited) (US$000’s) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Cash flows from operating activities Loss for the period (5,135) (4,759) (19,900) (14,833) Adjustments to reconcile loss to cash used i
Slide 14: Consolidated Statement of Cash Flows (unaudited)
Trinity Biotech PLC Consolidated Statement of Cash Flows (unaudited) (US$000’s) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Cash flows from financing activities Issue of ordinary share capital including share premium (net of issuance costs) - 7,117 547 6,847
Slide 15: Investor Queries
Investor Queries Trinity Biotech Plc RedChip Companies Inc Paul Murphy David Gentry (353)-1-2769800 (1)-407-644-4256 investorrelations@trinitybiotech.com TRIB@redchip.com